Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases

The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non‐oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non‐oncological diseases and (b) the risk–benefit ratio of treating p...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Pharmacol
Main Authors: Berger, Nathan A, Besson, Valerie C, Boulares, A Hamid, Bürkle, Alexander, Chiarugi, Alberto, Clark, Robert S, Curtin, Nicola J, Cuzzocrea, Salvatore, Dawson, Ted M, Dawson, Valina L, Haskó, György, Liaudet, Lucas, Moroni, Flavio, Pacher, Pál, Radermacher, Peter, Salzman, Andrew L, Snyder, Solomon H, Soriano, Francisco Garcia, Strosznajder, Robert P, Sümegi, Balázs, Swanson, Raymond A, Szabo, Csaba
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2017
Fag:
Themed Section: Review Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5758399/
https://ncbi.nlm.nih.gov/pubmed/28213892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13748
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker